ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
vTv Therapeutics Inc

vTv Therapeutics Inc (VTVT)

23.51
0.91
(4.03%)
Closed July 23 4:00PM
23.51
0.00
( 0.00% )
Pre Market: 7:24AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
23.51
Bid
9.40
Ask
25.00
Volume
-
0.00 Day's Range 0.00
7.38 52 Week Range 31.20
Market Cap
Previous Close
23.51
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
11,665
Shares Outstanding
3,010,206
Dividend Yield
-
PE Ratio
-3.49
Earnings Per Share (EPS)
-6.73
Revenue
-
Net Profit
-20.25M

About vTv Therapeutics Inc

vTv Therapeutics Inc operates in the United States healthcare sector. Its key business includes the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as Alzheimer's disease. Its major drug candidate to treat Alzheimer's is azeliragon (... vTv Therapeutics Inc operates in the United States healthcare sector. Its key business includes the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as Alzheimer's disease. Its major drug candidate to treat Alzheimer's is azeliragon (TTP488), an orally administered drug. Its other products include TTP399, type II diabetes drug candidate. TTP399 is also an orally administered drug that targets the glucagon-like peptide-1 receptor. It also has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
vTv Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VTVT. The last closing price for vTv Therapeutics was $23.51. Over the last year, vTv Therapeutics shares have traded in a share price range of $ 7.38 to $ 31.20.

vTv Therapeutics currently has 3,010,206 shares outstanding. The market capitalization of vTv Therapeutics is $70.77 million. vTv Therapeutics has a price to earnings ratio (PE ratio) of -3.49.

VTVT Latest News

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING PR Newswire WESTON, Fla., May 28, 2024 WESTON, Fla., May 28, 2024 /PRNewswire/...

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

HIGH POINT, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin...

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT PR Newswire WESTON, Fla., March 19, 2024 Podium presentation will include clinical updates from the Company's...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.110.47008547008523.424.8219.913610622.82237989CS
46.437.405026300417.1124.916.31012479221.13719006CS
12-3.84-14.040219378427.3529.1216.251166521.80052283CS
2614.26154.1621621629.2530.997.384135217.26506231CS
52-6.09-20.574324324329.631.27.388048521.41818093CS
156-57.29-70.903465346580.886.87.3834722548.38687937CS
260-31.69-57.409420289955.2205.27.3891690298.88841564CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NUZENuZee Inc
$ 4.26
(313.59%)
24.19M
DRMADermata Therapeutics Inc
$ 3.45
(165.38%)
20.02M
BBLGBone Biologics Corporation
$ 2.149
(71.92%)
8.85M
PIRSPieris Pharmaceuticals Inc
$ 13.65
(71.05%)
1.16M
HOTHHoth Therapeutics Inc
$ 1.43
(47.13%)
19.49M
CONNConns Inc
$ 0.3202
(-36.84%)
236.16k
NUWENewellis Inc
$ 2.76
(-33.49%)
73.39k
VWEVintage Wine Estates Inc
$ 0.0779
(-30.38%)
2.09M
VSTMVerastem Inc
$ 2.67
(-25.63%)
214.73k
ATPCAgape ATP Corporation
$ 0.16
(-25.58%)
869.51k
SLNASelina Hospitality PLC
$ 0.0259
(-0.38%)
41.4M
ALLRAllarity Therapeutics Inc
$ 0.2098
(26.01%)
38.06M
NUZENuZee Inc
$ 4.26
(313.59%)
24.19M
DRMADermata Therapeutics Inc
$ 3.45
(165.38%)
20.02M
HOTHHoth Therapeutics Inc
$ 1.43
(47.13%)
19.49M

VTVT Discussion

View Posts
Awl416 Awl416 5 months ago
vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund
πŸ‘οΈ0
dennisv dennisv 6 months ago
Cowboys2275: You Are Really A Special Cowboy!
https://stocktwits.com/cowboys2275/message/558967191
πŸ‘οΈ0
dennisv dennisv 6 months ago
There will be More interest in VTVT!
πŸ‘οΈ0
dennisv dennisv 6 months ago
https://zolmax.com/investing/vtv-therapeutics-inc-nasdaqvtvt-sees-large-increase-in-short-interest/9990102.html
πŸ‘οΈ0
dennisv dennisv 6 months ago
American Bulls: Buy Signal!
https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=VTVT
πŸ‘οΈ0
Monksdream Monksdream 10 months ago
VTVT new 52 week low
πŸ‘οΈ0
AJ Freely AJ Freely 11 months ago
$VTVT- 👆Up 16% Pre-Market/Current Price $0.78
👉Cantex Pharmaceuticals Publishes Article in npj Breast Cancer Highlighting Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer
👉Originally developed for Alzheimer's disease by vTv
πŸ‘οΈ0
81vette 81vette 1 year ago
2 week long runs in past on news and this is awesome news
πŸ‘οΈ0
81vette 81vette 1 year ago
Zero borrow and not optionable,low float target $4,insider trans up 145%
πŸ‘οΈ0
81vette 81vette 1 year ago
Zero borrow and not optionable,low float target $4,insider trans up 145%
πŸ‘οΈ0
TheFinalCD TheFinalCD 1 year ago
https://finviz.com/quote.ashx?t=VTVT&ty=c&ta=1&p=d
πŸ‘οΈ0
N-13 N-13 2 years ago
I guess I spoke too soon.
πŸ‘οΈ0
N-13 N-13 2 years ago
Wow, we closed over 70 cents!
πŸ‘οΈ0
Investor2014 Investor2014 2 years ago
Because the company keeps spending and raising money without achieving anything.
πŸ‘οΈ0
N-13 N-13 2 years ago
Why, so difficult to get over 70 cents?
πŸ‘οΈ0
N-13 N-13 2 years ago
What's with the knuckleheads that are trading pre and post market?
πŸ‘οΈ0
surf1944 surf1944 2 years ago
https://stockcharts.com/h-sc/ui?s=VTVT&p=D&yr=0&mn=6&dy=0&id=p38090673899

Filled open gap .62 this morning!
πŸ‘οΈ0
Golden Cross Golden Cross 2 years ago
$VTVT Huge Vol Alert
πŸ‘οΈ0
cjstocksup cjstocksup 2 years ago
@bc9114 The $12.5m ( 5,193,187 shares) in shares distribution to G42 Healthcare were dilutive shares resulting in a increase in total outstanding shares from 90,036,637 to 95,229,824. The float will remain at 30,346,158 because G42 Healthcare will become an affiliate in the next 30 days.

β€œLock-Up Period” means the period from the date of this Agreement until December 31, 2024 (or, if earlier, the date of receipt of FDA Approval). I love this Lock-Up Period : ) which is located on page 5.

These particular shares are classified as Unregistered Securities that orginated from the LPC Agreement which had $35.9 remaining available as of March 31st, 2022 & as a result of the G42 Healthcare Partnership the remaining availability under the LPC Agreement is now at $23.4m.

Common Stock Purchase Agreement: (Unregistered Securities)
sec.gov/Archives/edgar/data...

In the next 30 days Vtv's board will increase to 6 & will add
Dr. Fahed Al Marzooqi the COO of G42 Healthcare.
πŸ‘οΈ0
cjstocksup cjstocksup 2 years ago
Read today's news it already happened at $2.41 per share.
πŸ‘οΈ0
Pt3 Pt3 2 years ago
What a good talk ....when is offering
πŸ‘οΈ0
cjstocksup cjstocksup 2 years ago
We churned over the float but those who bought premarket up to $1.18 panic sold on the red open and the rest of the day others panic sold red down. Bottom line the 25-million-dollar investment is huge. We should be up a couple dollars. I am patient. We have more news on the way.
VTVT: This could run-up nicely today, behind substantive news of late and a $5.00 price prediction.
πŸ‘οΈ0
Pt3 Pt3 2 years ago
What going on here bulls ....just bought 5000 shares need info
πŸ‘οΈ0
crudeoil24 crudeoil24 2 years ago
Yes, I read that filing earlier!
πŸ‘οΈ0
cjstocksup cjstocksup 2 years ago
New SEC Filing: 8-K Material Agrmt - vTv Therapeutics Inc. (0001641489) May 31


Item 1.01Entry into a Material Definitive Agreement Common Stock Purchase Agreement On May 31, 2022, vTv Therapeutics Inc. (the "Company") and G42 Investments AI Holding RSC Ltd, a private limited company ("G42 Investments"), entered into a common stock purchase agreement (the "Purchase Agreement"), pursuant to which the Company agreed to sell to G42 Investments 10,386,274 shares of the Company's Class A common stock, par value $0.01 per share (the "Common Stock" and such shares, the "Closing Shares") at a price per share of approximately $2.41, for an aggregate purchase price of $25,000,000, which was paid (i) $12,500,000 in cash at the closing of the transaction and (ii) $12,500,000 in the (...)

marketnewswire.live/index.p...
πŸ‘οΈ0
Awl416 Awl416 2 years ago
News
πŸ‘οΈ0
crudeoil24 crudeoil24 2 years ago
vTv Therapeutics Announces Entry Into Agreements That Include $25M Investment By G42 Investments AI Holding RSC
6:56 am ET June 1, 2022 (Benzinga) Print
vTv Therapeutics Inc. (NASDAQ:VTVT) today announced entry into agreements that include a $25 million investment by G42 Investments AI Holding RSC Ltd ("G42 Investments"). Under the terms of the agreements, G42 Investments acquired 10,386,274 shares of Class A Common Stock of vTv at an issue price of $2.407 per share, with $12.5 million paid in cash at closing, and the remaining amount of $12.5 million payable on May 31, 2023. The agreements also provide for the potential issuance of $30 million in additional shares of Class A Common Stock to G42 Investments (or cash in lieu of such issuance at the option of G42 Investments) if the United States Food and Drug Administration (the "FDA") approves the marketing and sale of a pharmaceutical product containing TTP399, a liver selective glucokinase activator, as the active ingredient for treatment of type 1 diabetes in the United States. The agreements set forth the terms under which vTv and an affiliate of G42 plan to collaborate on clinical trials for pharmaceutical products that contain TTP399, including G42's affiliate funding a portion of the Phase 3 clinical trials for TTP399, and vTv granting G42's affiliate an exclusive license to develop and commercialize pharmaceutical products containing TTP399 in certain territories outside of the United States and the European Union.

"We have focused substantial energy and resources on TTP399 since obtaining Breakthrough Therapy designation from the FDA in April 2021 and are thrilled to welcome a partner to work with us to accelerate the development and potential approval and commercialization of this treatment. G42 Healthcare brings a unique combination of strong commitment to the development of new impactful drugs and treatments, as demonstrated by their success and their leadership on COVID-19 testing and other product and service offerings in the healthcare spectrum, and substantial resources, making them an ideal partner for this program. This investment into vTv will fund a substantial portion of our Phase 3 clinical trials for TTP399 in the United States and the collaboration with G42 will fund certain of the Phase 3 clinical trials that will be conducted in other territories. We are excited to partner with the G42 Healthcare team as we launch our Phase 3 clinical trials and work together towards approval and commercialization of this treatment for type 1 diabetes," said Rich Nelson, Interim Chief Executive Officer of vTv.

Dr. Fahed Al Marzooqi, the Chief Operating Officer of G42 Healthcare, noted that "We have a deep commitment to collaborating with international organizations to share our knowledge and expertise in the consumer and clinical health spectrum and we look forward to working together with vTv to further develop and commercialize this important treatment. As we move ahead, we will continue to join forces with the world's best to innovate and invest in science and create the next wave of medicines to future-proof the health of nations."

A more detailed description of the agreements is set forth in vTv's Current Report on Form 8-K filed with the SEC. The Stock Purchase Agreement is attached to the Current Report on Form 8-K and the Collaboration and License Agreement will be filed with vTv's Quarterly Report on Form 10-Q for the second quarter.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor will there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
πŸ‘οΈ0
Investor2014 Investor2014 2 years ago
Or drop big
πŸ‘οΈ0
TommyBoyTrader9460 TommyBoyTrader9460 2 years ago
$VTVT
$VTVT Licking my chops with this chart..looks like $1 could be tested soon here.. just added to the Post Masters Telegram Room watchlist..we deliver!https://t.co/qZaQQOjnVVhttps://t.co/1HSlQfNws7 pic.twitter.com/SHqV52fAbw— Tommy Boy Trader (@QuabbinR) February 20, 2022
πŸ‘οΈ0
Just-Keep-Trying Just-Keep-Trying 2 years ago
VTVT: This could run-up nicely today, behind substantive news of late and a $5.00 price prediction.
πŸ‘οΈ0
Tom turtles Tom turtles 3 years ago
Really not till the start of 2022....but you never know when they'll drop a biggie
πŸ‘οΈ0
murocman murocman 3 years ago
I am surprised this has not gotten more traction and visibility after releasing good trial data.

The Type 1 diabetes market is huge.

Any catalysts in the near term to help out?

Murocman
πŸ‘οΈ0
Tom turtles Tom turtles 3 years ago
Too cheap to ignore here !
πŸ‘οΈ0
Tom turtles Tom turtles 3 years ago
DWAC.....craziness
πŸ‘οΈ0
murocman murocman 3 years ago
Likely because they are woefully behind on their financial filings.

Murocman
πŸ‘οΈ0
Tom turtles Tom turtles 3 years ago
Well look at ADMP......they get FDA approval and the stock sells off......ya never know. GL with your trades...
πŸ‘οΈ0
Investor2014 Investor2014 3 years ago
P2 trials planned to initiate in 2022. I can’t see those increasing $VTVT as just adding more cost and likely more dilution.

The price of $VTVT going up is linked to the success of those trials.

I might invest at some point before readout if I think the risk/reward looks attractive. Need to see P2 trial protocols first.
πŸ‘οΈ0
Tom turtles Tom turtles 3 years ago
Just need it to get past $3 over the next year. Think that's very doable. ITRM and ADMP couple others I'm watching.
πŸ‘οΈ0
Tom turtles Tom turtles 3 years ago
Most of his shares were bought above $4. He recently bought 635,000 @ $1.60. I'm closing in on 100,000 shares. Hope I didn't make a mistake here.... Their trials haven't been very successful lately , and recently raised the O/S to 200M shares, which is still very low for a buck stock. ~ You have any other pharm plays that are ripe ? TIA.....
πŸ‘οΈ0
Investor2014 Investor2014 3 years ago
Perelman has years ago signed an agreement with vTv funding them on demand by buying the shares they issue.

Insider buying on that basis doesn’t tell you very much other than perhaps Perelman may be a sucker holding a big bag.
πŸ‘οΈ0
Tom turtles Tom turtles 3 years ago
It seems he owns about 80% of the company. Not sure how many shares he owns....couldn't find that number on insider trades...
πŸ‘οΈ0
Tom turtles Tom turtles 3 years ago
You like this thing Invest2014 ? Right now looks bad.....but 2022 is gonna be huge. Why not accum now...and put in a drawer for a year. No doubt this will bust $5 next year. Been picking up all these $1.40s..New CEO.....inside buying ....lots of things going on here. Huge pipeline...Not just one and done drug. Picking up this and SYN for a long hold.
πŸ‘οΈ0
Investor2014 Investor2014 3 years ago
It seems you can have most of the $VTVT that Perelman doesn’t own.
πŸ‘οΈ0
Tom turtles Tom turtles 3 years ago
Almost filled up.
πŸ‘οΈ0
Tom turtles Tom turtles 3 years ago
Bye buy bye buy
πŸ‘οΈ0
Tom turtles Tom turtles 3 years ago
What a turd
πŸ‘οΈ0
Tom turtles Tom turtles 3 years ago
I'll be able to buy that new Range Rover I've been looking at.....with cash !
πŸ‘οΈ0
Tom turtles Tom turtles 3 years ago
Lol.....hi 1plus1....yes....this is shit right now.....That's why I'm accumulating this for a year from now. Insiders buying in this range...and not just teaser purchases....big buys. This one I'm putting in my closet for next year. Almost have 100,000 shares. Now RNVA you have to watch everyday.....never know when shameless will pull the plug....GL man
πŸ‘οΈ0
1plus1 1plus1 3 years ago
This thing is taking the shitzzzz Rnva is a way better buy
πŸ‘οΈ0
Tom turtles Tom turtles 3 years ago
Thanks for all the cheapies fellas.....now wait time. Back to $4 sometime this spring. All I have is time !
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock